This procedure led to 1,000–2,000 permutations of null hypothesis CNV sets each for the bipolar, schizophrenia, and control de novo CNV sets. Significance for each of the query pathways was assessed by counting the number of pathway genes impacted by each null hypothesis CNV set, thus leading selleck chemicals llc to a null distribution against which we could compare the number of observed hits and calculate enrichment p values. Second we applied a case-control CNV enrichment test implemented in PLINK (http://pngu.mgh.harvard.edu/∼purcell/plink/) to the eight gene sets (pathways) associated
with SCZ de novo CNVs and seven gene sets associated with BD de novo CNVs. For analysis of de novo CNVs using PLINK we report the one-sided empirical p value based on 10,000 permutations. A category was defined as “enriched” if nominally significant (p < 0.05) by all case-only and case-control permutation tests. Pathway enrichment analysis was also applied to de novo CNVs in control, and significance was based on a single (control only) permutation test. We extended our analysis of pathways identified in this study (Table 4 and Table 5, and S7) to
rare CNVs from large case-controls studies of SCZ and BD. These included rare CNVs from 8,290 SCZ cases and 7,431 controls from Vacic et al. (2011), a combined sample of three studies from our group, MGS (Levinson et al., 2011), and the International Schizophrenia Consortium (International Schizophrenia Consortium, 2008), and a BD case-control data set consisting Sunitinib cost of 2,777 cases and 3,508 controls from BiGS study (Smith et al., 2009). Pathway enrichment was assessed using the case-control CNV enrichment test implemented in PLINK. We thank all patients and their families for their participation in this genetic study. Special thanks to James Watson for helpful discussions and support. This study was supported by a gift from Ted and Vada Stanley to the Cold Spring Harbor Laboratory, a gift to J.S. from the Beyster family foundation, NIH grants to J.S. (MH076431, HG04222), D.L.L. (MH071523), and
M.K. (MH061399), grants to J.S. and D.L.L. from NARSAD, grants ADP ribosylation factor to A.C. and M.G. from the Wellcome Trust (072894/Z/03/Z) and Science Foundation Ireland (08INIB1916), and grants to D.L.L. from the Sidney R. Baer, Jr. Foundation and Essel Foundation. We thank the Genetic Association Information Network (GAIN), Molecular Genetics of Schizophrenia (MGS), and the Bipolar Genome Study (BiGS) for providing data for this study. We thank Roche NimbleGen and Oxford Gene Technology for their expert technical assistance. We thank Lilia M. Iakoucheva and Roser Corominas for helpful discussions. “
“Sleep is an essential and conserved animal behavior. In humans, sleep occupies approximately one-third of life, and its importance is underscored by the overpowering drive to obtain sleep after a period of sleep deprivation.